NIZHNY NOVGOROD (Marker.ru) – Russian pharmaceutical company Nizhpharm has announced the launch of full-cycle production of the type 2 diabetes drug Incresync at its plant in Obninsk.
The drug is a fixed-dose combination of two glucose-lowering agents, alogliptin and pioglitazone. The company emphasizes that Incresync has undergone a full cycle of clinical trials and is intended for the treatment of adult patients over 18 years of age.
The production launch comes amid a rise in diabetes prevalence in Russia. According to official data, more than 5.8 million Russians have been diagnosed with diabetes as of early 2025. However, experts believe the actual number of patients could reach 12 million people, nearly double the official statistics.
Nizhpharm CEO Dmitry Isachenko stated that the localization of production is aimed at improving the accessibility of therapy. “By 2030, we plan to produce 2 million packages per year, which will provide over 150,000 patients with stable access to a domestically produced drug,” he said, adding that the project also contributes to expanding production capacity and creating new jobs.
The company added that the technology transfer for manufacturing Incresync required significant investment and strict adherence to international GMP quality standards.